## Supporting Information

## Simple enrichment and analysis of plasma lysophosphatidic acids

Jialu Wang,<sup>*a*</sup> Martha Sibrian-Vazquez,<sup>*a*</sup> Jorge O. Escobedo,<sup>*a*</sup> Mark Lowry,<sup>*a*</sup> Lei Wang,<sup>*a*</sup> Yu-Hsuan Chu,<sup>*a*</sup> Richard G. Moore,<sup>*b*</sup> and Robert M. Strongin,\*<sup>*a*</sup>

<sup>a</sup> Department of Chemistry, Portland State University, Portland, OR 97201, USA.

*E-mail: strongin@pdx.edu; Tel: +1 503-725-9724* 

<sup>&</sup>lt;sup>b</sup> Women and Infants Hospital, Brown University, 101 Dudley Street, Providence, RI 02905, USA.; E-mail: RMoore@wihri.org; Tel: +1 401-453-7520

## **Table of Contents**

Page

Fig. S1. Mass spectra of phospholipids mixture in negative mode	<b>S</b> 3
Fig. S2. Mass spectra of phospholipids mixture in positive mode	<b>S</b> 3
Fig. S3. Mass spectra of plasma extract in negative mode	<b>S</b> 4
Fig. S4. Mass spectra of plasma extract in positive mode	S4
<b>Table S1.</b> Effect of column length on the resolution and theoretical plates for the separation of LPAs	S5
<b>Table S2.</b> Effect of pH on the resolution and theoretical plates for the separation of LPAs	S5
<b>Table S3.</b> Resolution and theoretical plates for the final optimal conditions	S5
<b>Table S4.</b> Results for LPA analysis in human plasma (donor B) using the HPLC post-column fluorescence and LC/ESI/MS/MS methods.	<b>S</b> 6
<b>Table S5.</b> Results for LPA analysis in human plasma (donor C) using the HPLC post-column fluorescence and LC/ESI/MS/MS methods.	<b>S</b> 6
<b>Table S6.</b> Results for LPA analysis in human plasma (donor D) using the HPLC post-column fluorescence and LC/ESI/MS/MS methods	<b>S</b> 7
<b>Table S7.</b> Results for LPA analysis in human plasma (donor E) using the HPLC post-column fluorescence and LC/ESI/MS/MS methods	<b>S</b> 7



Fig. S1 Mass spectra of phospholipids mixture in negative mode.



Fig. S2 Mass spectra of phospholipids mixture in positive mode.



Fig. S3 Mass spectra of plasma extract in negative mode.



Fig. S4 Mass spectra of plasma extract in positive mode.

	LPA 14:0		LPA 20:4		LPA 16:0		LPA 18:1		LPA 17:0		LPA 18:0
column length (mm)	<i>N</i> ( <i>RT</i> , min)	$R_s$	<i>N</i> ( <i>RT</i> , min)								
100 <sup>b</sup>	312 (4.44)	2.31	192 (5.56)	1.35	1715 (6.53)	NA	NA (7.89)	NA	2712 (8.71)	7.74	3001 (11.87)
50 <sup>c</sup>	1280 (3.83)	4.40	1486 (4.72)	3.52	1917 (5.44)	4.30	1748 (6.61)	2.57	3416 (7.32)	10.04	4361 (10.50)

Table S1. Effect of column length on the resolution and theoretical plates for the separation of LPAs.<sup>a</sup>

<sup>*a*</sup> Rs = resolution, N = theoretical plates, RT = retention time, NA = not applicable; LPA concentration: 80 μM; mobile phase: 4/1 MeOH/50 mM pH 3.0 phosphate buffer; injection volume: 5 μL.

<sup>b</sup>Discovery Bio wide pore (Supelco), C-8, 3 µm, 2.1 mm diameter. Flow rate: 0.20 mL/min.

<sup>c</sup>Luna (Phenomenex), C-8, 3 µm, 2.0 mm diameter. Flow rate: 0.20 mL/min.

**Table S2.** Effect of pH on the resolution and theoretical plates for the separation of LPAs.<sup>*a*</sup>

			pri on me	10010	and and a		real praces		- separation		101
	LPA 14:0		LPA 20:4		LPA 16:0		LPA 18:1		LPA 17:0		LPA 18:0
pН	Ν	$R_s$	Ν								
	( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)
3.0	996 (3.01)	7.93	1302 (4.69)	3.14	1040 (5.59)	4.22	1860 (6.92)	1.65	397 (7.78)	5.66	2176 (11.12)
2.5	1331 (3.16)	9.71	2000 (4.85)	3.41	1862 (5.61)	4.82	1625 (6.99)	2.56	1630 (7.88)	7.57	1828 (11.21)

 ${}^{a}Rs$  = resolution, N = theoretical plates, RT = retention time; LPA concentration is 5  $\mu$ M; column: Luna C-8 50 × 2.0 mm; mobile phase: 7/2 MeOH/50 mM phosphate buffer; flow rate: 0.27 mL/min. Injection volume: 20  $\mu$ L.

	1, 6,1 6	1 1	1 a
I able 53. Resolution and theoretical	plates for the fi	nal optimal	conditions.

					-						
	LPA 14:0		LPA 20:4		LPA 16:0		LPA 18:1		LPA 17:0		LPA 18:0
-	Ν	$R_s$	Ν								
	( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)		( <i>RT</i> , min)
	848 (3.96)	6.25	1149 (5.76)	3.75	2531 (6.84)	5.71	2105 (8.58)	2.65	1278 (9.72)	8.28	2635 (13.96)

<sup>*a*</sup> Column: Luna C-8 50  $\times$  2.0 mm; LPA concentration is 10  $\mu$ M; mobile phase: 16/5 MeOH/50 mM phosphate buffer; flow rate: 0.32 mL/min. Injection volume: 20  $\mu$ L.

	non-sp	iked	spiked with 0	.5 µM LPA	$\mathbf{D}$	
	$\mu M$ (average, $\sigma$ )		μM (aver	age, σ)	Recovery (%)	
	HPLC	LC/ESI	HPLC LC/ESI		HPLC	LC/ESI
	Post-Column	MS/MS	Post-Column	MS/MS	Post-Column	MS/MS
LPA 14:0	0.97(0.03)	1.03(0.01)	1.43(0.04)	1.45(0.03)	94	82
LPA 20:4	0.98(0.01)	0.94(0.01)	1.41(0.02)	1.43(0.01)	86	100
LPA 16:0	0.96(0.02)	1.04(0.02)	1.45(0.03)	1.60(0.03)	98	112
LPA 18:1	1.05(0.00)	1.03(0.02)	1.47(0.02)	1.55(0.02)	84	102
LPA 18:0	0.99(0.01)	0.93(0.01)	1.56(0.04)	1.47(0.01)	114	110
Total LPA	4.96(0.04)	4.97(0.04)	7.33(0.01)	7.50(0.08)	95	101

**Table S4** Results for LPA analysis in human plasma (donor B) using the HPLC post-column fluorescenceand LC/ESI/MS/MS methods (n = 3).

**Table S5** Results for LPA analysis in human plasma (donor C) using the HPLC post-column fluorescenceand LC/ESI/MS/MS methods (n = 3).

	non-sp	iked	spiked with 0	.5 µM LPA	$\mathbf{P}_{\alpha\alpha\alpha\nu}(0/2)$	
	$\mu M$ (average, $\sigma$ )		μM (aver	age, σ)	Keeovery (%)	
	HPLC	LC/ESI	HPLC	LC/ESI	HPLC	LC/ESI
	Post-Column	MS/MS	Post-Column	MS/MS	Post-Column	MS/MS
LPA 14:0	0.76(0.01)	0.68(0.02)	1.25(0.02)	1.21(0.04)	98	106
LPA 20:4	0.21(0.02)	0.27(0.02)	0.64(0.01)	0.67(0.05)	84	80
LPA 16:0	0.55(0.01)	0.42(0.04)	1.05(0.05)	0.97(0.04)	100	112
LPA 18:1	0.37(0.01)	0.32(0.01)	0.96(0.05)	0.79(0.06)	120	96
LPA 18:0	0.29(0.03)	0.23(0.01)	0.79(0.01)	0.79(0.02)	102	112
Total LPA	2.18(0.02)	1.91(0.09)	4.69(0.08)	4.44(0.12)	100	101

	non-sp	iked	spiked with 0	.5 µM LPA	$\mathbf{B}_{222}$	
	$\mu M$ (average, $\sigma$ )		μM (aver	age, σ)	Recovery (%)	
	HPLC	LC/ESI	HPLC LC/ESI		HPLC	LC/ESI
	Post-Column	MS/MS	Post-Column	MS/MS	Post-Column	MS/MS
LPA 14:0	0.24(0.00)	0.23(0.01)	0.65(0.02)	0.68(0.02)	82	92
LPA 20:4	0.26(0.01)	0.28(0.01)	0.67(0.01)	0.65(0.04)	82	74
LPA 16:0	0.45(0.03)	0.43(0.01)	0.88(0.02)	0.83(0.04)	88	80
LPA 18:1	0.30(0.02)	0.38(0.01)	0.87(0.02)	0.85(0.03)	114	94
LPA 18:0	0.33(0.02)	0.31(0.00)	0.85(0.02)	0.82(0.01)	104	102
Total LPA	1.57(0.03)	1.63(0.03)	3.91(0.03)	3.83(0.12)	94	88

**Table S6** Results for LPA analysis in human plasma (donor D) using the HPLC post-column fluorescenceand LC/ESI/MS/MS methods (n = 3).

**Table S7** Results for LPA analysis in human plasma (donor E) using the HPLC post-column fluorescenceand LC/ESI/MS/MS methods (n = 3).

	non-sp	iked	spiked with 0	.5 µM LPA	$\mathbf{D}$	
	$\mu M$ (average, $\sigma$ )		μM (aver	age, σ)	Kecovery (%)	
	HPLC	LC/ESI HPLC		LC/ESI	HPLC	LC/ESI
	Post-Column	MS/MS	Post-Column	MS/MS	Post-Column	MS/MS
LPA 14:0	0.17(0.00)	0.18(0.01)	0.61(0.02)	0.60(0.00)	86	84
LPA 20:4	0.20(0.02)	0.23(0.01)	0.75(0.01)	0.77(0.01)	110	110
LPA 16:0	0.29(0.00)	0.28(0.02)	0.71(0.00)	0.76(0.01)	84	96
LPA 18:1	0.53(0.01)	0.47(0.02)	0.97(0.02)	1.03(0.00)	90	112
LPA 18:0	0.33(0.00)	0.30(0.01)	0.84(0.01)	0.89(0.00)	102	118
Total LPA	1.52(0.02)	1.45(0.05)	3.88(0.04)	4.06(0.01)	94	104